Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

Summary

This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

Timeline

Start

2021-10-22

Primary completion

2023-06-01

Completion

2023-06-01

Drugs

Indications